Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis ; volume:73 ; number:12 ; day:16 ; month:10 ; year:2024 ; pages:1 ; date:12.2024
Cancer immunology immunotherapy ; 73, Heft 12 (16.10.2024), 1, 12.2024

Creator: Chen, Yueying
Han, Hedong
Cheng, Jing
Cheng, Qinpei
Zhu, Suhua
Zhan, Ping
Liu, Hongbing
Song, ·Yong
Lv, Tangfeng

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00262-024-03819-x

URN: urn:nbn:de:101:1-2502040910583.567548295378

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:36 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Chen, Yueying
Han, Hedong
Cheng, Jing
Cheng, Qinpei
Zhu, Suhua
Zhan, Ping
Liu, Hongbing
Song, ·Yong
Lv, Tangfeng
SpringerLink (Online service)

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Related objects

Reset password